Analysis of Single Nucleotide Polymorphism A118g Gene Opioid Receptor Mu-1 (OPRM1) In Opioid Analgesic Patients in Indonesia

Mara Imam Taufiq Siregar, Arie Utariani^*, Hamzah, Elizeus Hanindito, Prananda Surya Airlangga and Retno Handajani

Abstract

Introduction: Opioid Receptor Mu-1 or Opioid Receptor Mu-1 (OPRM1) is a prime candidate for pharmacogenetic studies related to the variability of patient response to opioids. This variant is high frequency in Asian populations that is associated with differences in sensitivity and increased need for opioid analgesics in the treatment of pain. Therefore, this study was conducted with the aim of analyzing OPRM1 in patients receiving opioid analgesics in Indonesia, especially in the city of Surabaya.

Method: The method used is the Polymerase Chain Reaction–Restriction Fragment Length Polymorphism (PCR-RFLP), where the data collected is recorded and tabulated and then analyzed using SPSS version 20.0.

Result: The results showed that the frequency of SNP A118G of the OPRM1 gene was found to be quite high, namely 58 (72.5%) out of a total of 80 subjects. In 40 male subjects, the GG genotype frequency was found to be the highest at 19 (47.5%). While the genotype frequencies of AA, AG and GG were found to be almost comparable in women.

Conclusion: Therefore, it can be concluded that the frequency of SNP A118G of the OPRM1 gene was found to be high in the Indonesian population and had a high tendency in the male population, although it was not statistically significant.

Keywords:

OPRMI gene; SNP A118G; opioid receptors; Male and Female; PCR-RFLP

Cite This Article

Siregar, M. I. T., Utariani, A., Hamzah, Hanindito, E., Airlangga, P. S., Handajani, R. (2021). Analysis of Single Nucleotide Polymorphism A118g Gene Opioid Receptor Mu-1 (OPRM1) In Opioid Analgesic Patients in Indonesia. International Journal of Scientific Advances (IJSCIA), Volume 2| Issue 5: Sep-Oct 2021, Pages 754-758 , URL: https://www.ijscia.com/wp-content/uploads/2021/09/Volume2-Issue5-Sep-Oct-No.162-754-758.pdf

Volume 2 | Issue 5: Sep-Oct 2021